The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
GlobalData on MSN1d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback